A Retrospective Chart Review of BOTOX® and Xeomin® for the Treatment of Cervical Dystonia and Blepharospasm

Allergan

Status: Completed

Conditions: Cervical Dystonia; Blepharospasm

Treatments: Other: No Intervention

Study type: Observational

Funder types: Industry

Identifiers

NCT01814774

TRU2011

Details and patient eligibility

About

This study is a retrospective chart review to evaluate the doses of botulinum Type A toxins BOTOX® (onabotulinumtoxinA) and Xeomin® (incobotulinumtoxinA) used for the treatment of Cervical Dystonia and Blepharospasm in clinical practice.

Enrollment: 48 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• confirmed primary diagnosis of idiopathic cervical dystonia or blepharospasm for at least 2 years
• treatment with Xeomin® and BOTOX® for at least 1 year each

Exclusion criteria

• having a neuromuscular junction transmission disorder or taking any medications that could affect neuromuscular junction transmission
• previous surgical procedure involving bone or muscle for the management of cervical dystonia or blepharospasm

Trial design

48 participants in 2 patient groups

BOTOX®

Description:

Retrospective chart review of doses of BOTOX® (onabotulinumtoxinA) used as standard of care in clinical practice. No treatment (intervention) was administered.

Treatment:

Other: No Intervention

Xeomin®

Description:

Retrospective chart review of doses of Xeomin® (incobotulinumtoxinA) used as standard of care in clinical practice. No treatment (intervention) was administered.

Treatment:

Other: No Intervention